PCSK9 monokloonsed antikehad düslipideemia raviks: evolokumab ja alirokumab

Main Article Content

Alar Irs

Abstract

Euroopa Ravimiameti (European Medicines Agency, EMA) inimravimite komitee (Committee for Human Medicinal Products, CHMP) soovitas anda müügiloa kahele uuele sama toimemehhanismiga düslipideemiaravimile: evolokumabile (Repatha, Amgen) ja alirokumabile (Praluent, sanofi aventis).

 

Eesti Arst 2015; 94(9):567–570


Downloads

Download data is not yet available.

Article Details

How to Cite
Irs, A. (1). PCSK9 monokloonsed antikehad düslipideemia raviks: evolokumab ja alirokumab. Eesti Arst. https://doi.org/10.15157/ea.v0i0.12350
Section
RAVIMITEAVE RAVIMIAMETILT

Most read articles by the same author(s)

1 2 3 > >>